Presynaptic mechanisms of motor complications in Parkinson disease

Archives of Neurology

Volumn 64, Issue 1, 2007, Pages 141-143

  De La Fuente Fernández, Raúl ^a  

^a Universidad de La Coruña   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CARBIDOPA; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ARTICLE; DRUG EFFECT; DYSKINESIA; HUMAN; MEMBRANE VESICLE; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE; PRESYNAPTIC TERMINALS;

EID: 33846078664     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.1.141     Document Type: Article

References (15)

1. de la Fuente-Fernández R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain. 2004;127:888-899.
2. de la Fuente-Fernández R, Lu J-Q, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol. 2001;49:298-303.
3. de la Fuente-Fernández R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain. 2004;127:2747-2754.
4. Togasaki DM, Tan L, Protell P, Di Monte DA, Quik M, Langston JW. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol. 2001;50:254-257.
5. Calne DB, Zigmond MJ. Compensatory mechanisms in degenerative neurologic disorders: insights from parkinsonism. Arch Neurol. 1991;48:361-363.
6. Rizzoli SO, Betz WJ. The structural organization of the readily releasable pool of synaptic vesicles. Science. 2004;303:2037-2039.
7. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol. 1994;36:27-31.
8. Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D. Presynaptic regulation of dopaminergic neurotransmission. J Neurochem. 2003;87:273-289.
9. Nutt JG. Levodopa-induced dyskinesias: review, observations, and speculations. Neurology. 1990;40:340-345.
10. Kumar A, Huang Z, de la Fuente-Fernández R. Mechanisms of motor complications of treatment in Parkinson's disease. Adv Neurol. 2003;91:193-201.
11. Papa SM, Chase TM. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol. 1996;39:574-578.
12. Paquet M, Smith Y. Group I metabotropic glutamate receptors in the monkey striatum: subsynaptic association with glutamatergic and dopaminergic afferents. J Neurosci. 2003;23:7659-7669.
13. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol. 1989;25:523-526.
14. Rajput AH, Fenton ME, Di Paolo T, Sitte H, Pifl C, Hornykiewicz O. Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism Relat Disord. 2004;10:221-226.
15. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord. 2005;20:151-157.